What is the appropriate diagnostic workup and subsequent management plan for hilar cholangiocarcinoma?

Hilar Cholangiocarcinoma: Investigation and Management Plan

For suspected hilar cholangiocarcinoma, begin with ultrasound screening followed immediately by combined MRI with MRCP (the optimal initial investigation), then proceed to ERCP with brush cytology and endobiliary forceps biopsy for tissue diagnosis, reserving cholangioscopy-directed biopsies when initial attempts fail—this algorithmic approach maximizes diagnostic accuracy while assessing resectability to determine curative surgical candidacy versus palliative management. 1, 2

Initial Diagnostic Workup

First-Line Imaging (Sequential Approach)

Step 1: Ultrasound Screening

• Perform abdominal ultrasound as the initial investigation for suspected biliary obstruction 1
• Look specifically for: intrahepatic duct dilatation WITHOUT extrahepatic duct dilatation (classic pattern for hilar lesions)
• Use color Doppler to detect portal vein or hepatic artery compression/thrombosis
• Caveat: US frequently misses small perihilar tumors and cannot define tumor extent—it serves only as a screening tool 1

Step 2: MRI with MRCP (Preferred) or CT

• MRI with MRCP is the optimal initial investigation providing comprehensive information on: 1, 2
  • Liver and biliary anatomy with local tumor extent
  • Longitudinal extent of bile duct involvement
  • Hepatic parenchymal abnormalities and liver metastases
  • Hilar vascular involvement via MR angiography
• If MRI/MRCP unavailable: obtain contrast-enhanced spiral/helical CT of chest, abdomen, and pelvis 2
• For perihilar tumors with suspected portal venous/arterial involvement, contrast-enhanced spiral CT is essential 1

Tissue Acquisition Strategy (Hierarchical)

Primary Method: ERCP with Dual Sampling

• Perform ERCP with both brush cytology AND endobiliary forceps biopsy 2
• Brush cytology alone has only ~30% sensitivity; combined with forceps biopsy increases yield to 40-70% 1
• Critical limitation: Negative cytology does NOT exclude malignancy 1
• Improve cytology yield using thin preparations and cytospin techniques 1

Secondary Method: Cholangioscopy-Directed Biopsies

• If initial ERCP sampling is non-diagnostic, proceed to single-operator cholangioscopy (SpyGlass) 2, 3
• Take 4-6 biopsies under direct visualization for optimal sensitivity (77.4%) 3
• Provides incremental diagnostic yield of 27% over standard ERCP methods 2
• Particularly valuable for extrahepatic lesions with direct visual assessment

Alternative/Adjunct: EUS with Fine Needle Aspiration

• Consider EUS-guided FNA for regional lymph node sampling during staging 2
• Shows trend toward better sensitivity than ERCP brush cytology, though not statistically significant in all studies 2
• Critical warning: Avoid transperitoneal EUS biopsy if liver transplantation is being considered (risk of tumor seeding) 2

Tumor Markers (Adjunctive, Not Diagnostic)

• CA 19-9: Elevated in many cases but non-specific (also elevated in PSC, biliary obstruction, other malignancies) 1
• CEA: Raised in ~30% of cholangiocarcinoma patients 1
• CA-125: Elevated in 40-50%; may indicate peritoneal involvement 1
• These markers support diagnosis but cannot confirm or exclude malignancy

Comprehensive Staging (Once Diagnosis Suspected)

Mandatory Staging Investigations:

• Chest radiography (or thoracic CT if not already performed) 1, 2
• CT abdomen (if MRI/MRCP already done, this may be omitted) 1
• Laparoscopy: Most centers perform this to detect peritoneal or superficial liver metastases in patients considered resectable on imaging 1

Rationale: Up to 50% of patients are lymph node positive and 10-20% have peritoneal involvement at presentation 1

Management Algorithm Based on Resectability

Resectable Disease (Curative Intent)

Surgical Approach by Bismuth Classification: 1

• Bismuth I & II: En bloc resection of extrahepatic bile ducts and gallbladder + regional lymphadenectomy + Roux-en-Y hepaticojejunostomy
• Bismuth III: Above procedures PLUS right or left hepatectomy
• Bismuth IV: Above procedures PLUS extended right or left hepatectomy

Additional Surgical Considerations:

• Aim for tumor-free margin >5 mm 1
• Consider removing liver segment 1 (preferentially harbors metastases from hilar cholangiocarcinoma) for Bismuth stages II-IV 1
• Requires appropriate surgical and anesthetic expertise for major hepatobiliary procedures 1

Adjuvant Therapy:

• Offer 6-month capecitabine regimen after R0 or R1 resection in patients with good performance status (ECOG 0-1) within 16 weeks postoperatively 4
• Do NOT use gemcitabine alone or in combination for adjuvant therapy 4
• For R1 margins: consider 4-6 months capecitabine followed by chemoradiotherapy with capecitabine (discuss in MDT) 4

Expected Outcomes:

• 5-year survival: 9-18% for proximal lesions, 20-30% for distal lesions 1
• Median survival with perihilar tumor: 12-24 months 1
• Tumor-free margins and absence of lymphadenopathy are most important prognostic indicators 1

Unresectable or Metastatic Disease

First-Line Systemic Therapy:

• Cisplatin + gemcitabine + immunotherapy (durvalumab or pembrolizumab) is now standard of care 4
• CisGem backbone established by ABC-02 trial; immunotherapy addition (TOPAZ-1, Keynote-966) improves overall survival 4

Second-Line Therapy:

• FOLFOX regimen (ABC-06 trial) versus best supportive care 4
• Caveat: Benefit is modest (less than 1 month median OS improvement, 5% response rate) 4

Targeted Therapies (Molecular Testing Required):

• Test for IDH1/2, FGFR2, BRAF, HER2, MSI, NTRK mutations 4
• Ivosidenib for IDH1-mutated disease (only phase III trial showing PFS benefit) 4

Palliative Biliary Drainage:

• Avoid routine preoperative biliary drainage except for acute cholangitis 1
• For unresectable disease: endoscopic stenting preferred over surgical bypass 1
• ERCP or PTC allows stent insertion; choice depends on local expertise and anatomy 1
• Adequate biliary drainage improves survival in palliative setting 1

Liver Transplantation (Highly Selected Cases)

• Currently contraindicated as standard therapy (rapid recurrence, death within 3 years) 1
• May consider in clinical trials: preoperative chemoradiation followed by transplantation in carefully selected unresectable cases 1

Critical Pitfalls to Avoid

1. Do NOT obtain histologic confirmation via transperitoneal biopsy if transplantation is being considered (tumor seeding risk) 1, 2
2. Do NOT delay surgical assessment waiting for positive cytology—negative brushings do not exclude malignancy; up to 15% of suspected cases prove benign postoperatively 2, 5
3. Do NOT routinely drain bile ducts preoperatively—increases sepsis risk except in cholangitis 1
4. Do NOT assume lymphadenopathy means malignancy in PSC patients—common in PSC without malignant change 1
5. Remember that up to 20% of suspected cases are benign "Klatskin-mimicking lesions" including chronic cholangitis from stones 3, 5

Multidisciplinary Team Review

All suspected hilar cholangiocarcinoma cases require MDT review at initial presentation and after imaging/endoscopic procedures to optimize diagnostic accuracy and treatment planning 2, 6, 7